DOCSLIB.ORG

Effect of Heliox Breathing on Flow Limitation in Chronic Heart Failure Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Heliox Breathing on Flow Limitation in Chronic Heart Failure Patients Eur Respir J 2009; 33: 1367–1373 DOI: 10.1183/09031936.00117508 CopyrightßERS Journals Ltd 2009 Effect of heliox breathing on flow limitation in chronic heart failure patients M. Pecchiari*, T. Anagnostakos#, E. D’Angelo*, C. Roussos#, S. Nanas# and A. Koutsoukou# ABSTRACT: Patients with chronic heart failure (CHF) exhibit orthopnoea and tidal expiratory flow AFFILIATIONS limitation in the supine position. It is not known whether the flow-limiting segment occurs in the *Istituto di Fisiologia Umana I, Universita` degli Studi di Milano, peripheral or central part of the tracheobronchial tree. The location of the flow-limiting segment Milan, Italy, and can be inferred from the effects of heliox (80% helium/20% oxygen) administration. If maximal #Dept of Critical Care and Pulmonary expiratory flow increases with this low-density mixture, the choke point should be located in the Services, Evangelismos General central airways, where the wave-speed mechanism dominates. If the choke point were located in Hospital, Medical School, University of Athens, Athens, Greece. the peripheral airways, where maximal flow is limited by a viscous mechanism, heliox should have no effect on flow limitation and dynamic hyperinflation. CORRESPONDENCE Tidal expiratory flow limitation, dynamic hyperinflation and breathing pattern were assessed in M. Pecchiari 14 stable CHF patients during air and heliox breathing at rest in the sitting and supine position. Istituto di Fisiologia Umana I via L. Mangiagalli 32 No patient was flow-limited in the sitting position. In the supine posture, eight patients exhibited 20133 Milan tidal expiratory flow limitation on air. Heliox had no effect on flow limitation and dynamic Italy hyperinflation and only minor effects on the breathing pattern. Fax: 39 0250315430 The lack of density dependence of maximal expiratory flow implies that, in CHF patients, the E-mail: [email protected] choke point is located in the peripheral airways. Received: July 31 2008 KEYWORDS: Chronic heart failure, dynamic hyperinflation, expiratory flow limitation, heliox Accepted after revision: November 19 2008 idal expiratory flow limitation (EFL) at rest viscous mechanism (as is the case in normal STATEMENT OF INTEREST has been detected in both sitting and subjects at low lung volume), the flow-limiting None declared. T supine spontaneously breathing patients segment is located in the peripheral airways [4]. with acute heart failure [1], and in patients with chronic heart failure (CHF) in the supine position The aim of the present investigation was to assess alone [2]. At present, it is not known whether, in whether the tidal EFL exhibited by CHF patients CHF, the choke point is located in the central or in the supine position is located centrally or peripheral part of the tracheobronchial tree. Such peripherally. To this end, the density dependence localisation can be accomplished by studying the of EFL was studied by replacing inspired air with density dependence of maximal expiratory flow, heliox, a gas mixture three times less dense than and, consequently, the mechanisms by which air. The effect of heliox was assessed in terms of tidal EFL develops. According to the wave-speed maximal expiratory flows, dynamic hyperinfla- theory, flow limitation results from the coupling tion and breathing pattern, as previously between airway compliance and convective described in patients with stable chronic obstruc- acceleration of gas [3]. Since the pressure drop tive pulmonary disease (COPD) [5]. due to convective acceleration is density-depen- dent, the wave-speed theory states that the MATERIALS AND METHODS maximal expiratory flow increases with decreas- Stable ambulatory CHF patients (n514; one ing gas density. Flow limitation can also result female) with a mean¡SEM age of 57¡3 yrs were from the coupling between airway compliance studied. No patient had been hospitalised within and viscous pressure losses [3]. If flow is limited the 20 days preceding the study. Heart failure by this viscous mechanism, the maximal expira- was defined as symptomatic left ventricular tory flow is not expected to change when gas dysfunction with a left ejection fraction of ,0.45 density changes. When the maximal flow is documented by bidimensional echocardiogra- limited at wave speed (as is the case in normal phy. The congestive heart failure was post- subjects at high lung volume), the flow-limiting ischaemic in nine patients. No patient exhibited European Respiratory Journal segment is located in the central airways. In peripheral oedema. Three patients were current Print ISSN 0903-1936 c contrast, when the maximal flow is limited by a smokers, three nonsmokers and eight ex-smokers. Online ISSN 1399-3003 EUROPEAN RESPIRATORY JOURNAL VOLUME 33 NUMBER 6 1367 HELIOX BREATHING IN CHRONIC HEART FAILURE M. PECCHIARI ET AL. At the time of the study, 12 patients were being treated with the inspiratory part of the flow–volume loop of the control and diuretics, eight with b-blockers and four with digoxin. On the test breaths was poor. Patients were classified as non-flow- experimental day, Weber class was determined using cardio- limited, if the application of NEP increased expiratory flow pulmonary exercise testing [6]. Three patients were Weber class over the entire range of the control tidal volume, or flow- -1 -1 A (maximal oxygen uptake (V’O2,max)of.20 mL?kg ?min ), limited, if the control and test expiratory flow–volume loops -1 -1 four Weber class B (V’O2,max of 16–20 mL?kg ?min ), five superimposed at least in part (fig. 1). Two or three breaths after -1 -1 Weber class C (V’O2,max of 10–15 mL?kg ?min ) and two Weber each NEP test, the subjects inspired to total lung capacity -1 -1 class D (V’O2,max of ,10 mL?kg ?min ). Predicted V’O2,max (TLC) for assessment of inspiratory capacity (IC), and align- were computed using Wasserman’s equations [7]. Patients with ment of tidal flow–volume curves with respect to TLC. IC was primary pulmonary, neurological or myopathic diseases were measured as the difference between TLC and the end- excluded. In particular, to avoid the possible confounding expiratory volume of the control breath, and used to assess effects of subclinical COPD, patients were also excluded if their changes in dynamic hyperinflation, an approach that has been forced expiratory volume in 1 s (FEV1)/forced vital capacity shown to be reliable in COPD patients [12]. In each patient and (FVC) was ,75% [8]. To this end, before the beginning of the condition, a minimum of four acceptable IC manoeuvres, and experiments, spirometry was performed using standard meth- NEP applications were performed. ods and procedures [9], using a mass flow sensor (Vmax 22; Under all experimental conditions, three FVC manoeuvres SensorMedics Co., Yorba Linda, CA, USA), with reference were performed and the breathing pattern was assessed over a values being those of the European Coal and Steel Community 3-min period. Dyspnoea was measured under each experi- [9]. The study was approved by the Ethics Committee of mental condition using a 100-mm visual analogue scale (VAS). Evangelismos General Hospital (Athens, Greece) and each patient gave informed consent. Data, presented as mean¡SEM, were analysed using a mixed between–within-groups ANOVA. The correlation between The severity of chronic dyspnoea was assessed using the MMRC score and routine spirometric measurements was modified Medical Research Council (MMRC) scale [10]. examined using the nonparametric Spearman rank correlation. Patients were investigated while breathing air and 10 min after Statistical significance was taken at a p-value of f0.05. equilibration with heliox. Measurements were carried out first in the seated and then in the supine position (after 10 min in RESULTS the supine position). Air and heliox breathing were performed Sitting breathing air in random order. Table 1 shows the anthropometric characteristics and baseline lung function of the patients in the sitting position. FVC, FEV1, The assessment of tidal EFL was carried out by means of the expiratory reserve volume (ERV) and IC were reduced negative expiratory pressure (NEP) method [11]. Subjects, compared to predicted values. In this posture, none of the wearing a nose clip, breathed quietly through a flanged patients exhibited tidal EFL. Dyspnoea at rest was modest, as mouthpiece, a heated pneumotachometer (3830A; Hans indicated by the low VAS score (12¡2 mm). The significant Rudolph, Kansas City, MO, USA) connected to a differential correlation coefficients of MMRC versus the respiratory pressure transducer (Celesco LCVR-0005; Raytech variables are shown in table 2. MMRC correlated with Instruments, Vancouver, BC, Canada) and a low resistance percentage predicted IC, FVC and FEV1 (p50.006, 0.009 and two-way valve (2600; Hans Rudolph). The expiratory port of 0.038, respectively), as well as with age (p50.042) and the valve was connected to a Venturi device and the percentage predicted V’O2,max (p50.001). inspiratory port to a shutter (RV-12; AeroMech Devices, Almonte, ON, Canada). The Venturi device was connected via a solenoid valve to a high-pressure source and a regulator Supine breathing air allowed for a pre-set pressure (-5 cmH2O) at the airway Shifting to the supine position caused the FVC to decrease opening that was measured with a pressure transducer (change (D) in FVC -0.20¡0.04 L; p,0.01) and, as expected, IC (Celesco LCVR-0100; Raytech Instruments). The shutter was to increase (DIC 0.42¡0.09 L; p,0.01), whereas breathing connected through a three-way stopcock to the ambient air or pattern remained unchanged. In this position, eight (57%) to a large plastic bag containing humidified heliox at ambient patients became flow-limited. These patients had lower ERVs ¡ temperature. The patient was unaware of the gas mixture they than the non-flow-limited patients (0.25 0.04 versus ¡ were breathing.
Load more

Recommended publications
  • Lung Function Studies in Diagnostics and Follow-Up of Pulmonary Sarcoidosis
    Lung Function Studies in Diagnostics and Follow-up of Pulmonary Sarcoidosis By INGELA BRÅDVIK Lund 1994 From the Department of Lung Medicine and the Department of Clinical Physiology University of Lund, Sweden Lung Function Studies in Diagnostics and Follow-up of Pulmonary Sarcoidosis Ingela Brådvik Lund 1994 Organization Document name LUND UNIVERSITY DOCTORAL DISSERTATION Department of Lung Medicine Date of issue University Hospital 94 06 09 S-22I 85 Lund CODEN: ISRN LUMEDW/MELL- - 1007- - SE Authorfj) Sponsoring organization Ingela Brådvik The Swedish Heart Lung Foundation Title and subtitle Lung function studies in diagnostics and follow-up of pulmonary sarcoidosis Abstract In 66 patients the relationship between lung volumes and lung mechanics in pulmonary sarcoidosis was investigated Lung volumes, static lung mechanics, lung resistance, dynamic lung mechanics and arterial blood gases at rest and during exercise were obtained. Fifteen functionally compromised patients received steroids during one year. They were re-investigated during the treatment and at a follow-up after an average of 7 years. In another 41 patients with newly diagnosed sarcoidosis, the kinetics of the lung clearance of ^9mTc-DTPA measured over 180 minutes was explored, and compared to kinetics in healthy smokers. The relationship between lung clearance and lung volumes, lung mechanics, arterial blood gases and disease activity assessed with serum angiotensin-converting enzyme and "'Ga scintigraphy was studied. Reduced lung volumes and compliance, increased resistance and decreased arterial oxygen tension were common. Vital i capacity (VC), and changes of VC at follow-up, corresponded to the slope of the static elastic pressure/volume curve, . and to the variation of it.
    [Show full text]
  • Effect of an Indwelling Pleural Catheter Vs Talc Pleurodesis On
    This supplement contains the following items: 1. Original protocol, final protocol, summary of changes. 2. Original statistical analysis plan. There were no further changes to the original statistical analysis plan. Downloaded From: https://jamanetwork.com/ on 10/02/2021 The Australasian Malignant Pleural Effusion Trial (AMPLE) A Multicentre Randomized Study Comparing Indwelling Pleural Catheter vs Talc Pleurodesis in Patients with Malignant Pleural Effusions Ethics Registration number 2012-005 Protocol version number 1.0 Protocol date 10/01/2012 Authorised by: Name: Prof YC Gary Lee Role: Chief Investigator Signature: Date: 10/01/2012 Downloaded From: https://jamanetwork.com/ on 10/02/2021 General Information This document describes the Western Australian Randomised Malignant Effusion trial for the purpose of submission for review by the relevant human research and ethics committees. It provides information about procedures for entering patients into the trial and this protocol should not be used as a guide for the treatment of other patients; every care was taken in its drafting, but corrections or amendments may be necessary. Questions or problems relating to this study should be referred to the Chief Investigator or Trial Coordinator. Compliance The trial will be conducted in compliance with this protocol, the National Statement on Ethical Conduct in Human Research, data protection laws and other guidelines as appropriate. It will be registered with the Australia and New Zealand Clinical Trials Registry, once ethical approval is secured.
    [Show full text]
  • Bronchodilators Accelerate the Dynamics of Muscle O2 Delivery
    Chronic obstructive pulmonary disease Bronchodilators accelerate the dynamics of muscle Thorax: first published as 10.1136/thx.2009.120857 on 13 July 2010. Downloaded from O2 delivery and utilisation during exercise in COPD Danilo C Berton,1 Priscila B Barbosa,1 Luciana S Takara,1 Gaspar R Chiappa,1 Ana Cristina B Siqueira,1 Daniela M Bravo,1 Leonardo F Ferreira,2 J Alberto Neder1 See Editorial, p 573 ABSTRACT (QT), suggesting an important role for the central Background Expiratory flow limitation and lung cardiovascular adjustments in setting the limits of < Supplementary methods are hyperinflation promote cardiocirculatory perturbations increase in peripheral QO at the onset of exercise. published online only. To view 2 these files please visit the that might impair O2 delivery to locomotor muscles in Further experimental evidence for this contention journal online (http://thorax.bmj. patients with chronic obstructive pulmonary disease was obtained in a subsequent study in which com). (COPD). The hypothesis that decreases in lung hyperinflation a strategy aimed to reduce the resistive work of 1Pulmonary Function and Clinical after the inhalation of bronchodilators would improve breathing and dynamic hyperinflation (heliox) Exercise Physiology Unit skeletal muscle oxygenation during exercise was tested. simultaneously accelerated the dynamics of QTand (SEFICE), Division of Respiratory 5 Methods Twelve non- or mildly hypoxaemic males QO2 in patients with moderate to severe COPD. Diseases, Department of (forced expiratory volume in 1 s (FEV1)¼38.5612.9%
    [Show full text]
  • The Pulmonary Manifestations of Left Heart Failure*
    The Pulmonary Manifestations of Left Heart Failure* Brian K. Gehlbach, MD; and Eugene Geppert, MD Determining whether a patient’s symptoms are the result of heart or lung disease requires an understanding of the influence of pulmonary venous hypertension on lung function. Herein, we describe the effects of acute and chronic elevations of pulmonary venous pressure on the mechanical and gas-exchanging properties of the lung. The mechanisms responsible for various symptoms of congestive heart failure are described, and the significance of sleep-disordered breathing in patients with heart disease is considered. While the initial clinical evaluation of patients with dyspnea is imprecise, measurement of B-type natriuretic peptide levels may prove useful in this setting. (CHEST 2004; 125:669–682) Key words: Cheyne-Stokes respiration; congestive heart failure; differential diagnosis; dyspnea; pulmonary edema; respiratory function tests; sleep apnea syndromes Abbreviations: CHF ϭ congestive heart failure; CSR-CSA ϭ Cheyne-Stokes respiration with central sleep apnea; CPAP ϭ continuous positive airway pressure; Dlco ϭ diffusing capacity of the lung for carbon monoxide; DM ϭ membrane conductance; FRC ϭ functional residual capacity; OSA ϭ obstructive sleep apnea; TLC ϭ total lung ϭ ˙ ˙ ϭ capacity; VC capillary volume; Ve/Vco2 ventilatory equivalent for carbon dioxide early 5 million Americans have congestive heart For a detailed review of the pathophysiology of N failure (CHF), with 400,000 new cases diag- high-pressure pulmonary edema, the reader is re- nosed each year.1 Unfortunately, despite the consid- ferred to several excellent recent reviews.2–4 erable progress that has been made in understanding the pathophysiology of pulmonary edema, the pul- monary complications of this condition continue to The Pathophysiology of Pulmonary challenge the bedside clinician.
    [Show full text]
  • The Measurement of Pulmonary Diffusing Capacity for Carbon Monoxide by a Rebreathing Method
    THE MEASUREMENT OF PULMONARY DIFFUSING CAPACITY FOR CARBON MONOXIDE BY A REBREATHING METHOD Benjamin M. Lewis, … , Ernest J. Hayford-Welsing, Erma Flaherty J Clin Invest. 1959;38(11):2073-2086. https://doi.org/10.1172/JCI103985. Research Article Find the latest version: https://jci.me/103985/pdf THE MEASUREMENT OF PULMONARY DIFFUSING CAPACITY FOR CARBON MONOXIDE BY A REBREATHING METHOD*t By BENJAMIN M. LEWIS, TAI-HON LIN, FRANCES E. NOET AND ERNEST J. HAYFORD-WELSING§ WITH THE TECHNICAL ASSISTANCE OF ERMA FLAHERTY (From the Pulmonary Function Laboratories, Departments of Medicine, Wayne State University College of Medicine, and City of Detroit Receiving Hospital, Detroit, Mich.) (Submitted for publication February 18, 1959; accepted June 19, 1959) The pulmonary diffusing capacity for oxygen capacity and one second vital capacity are first determined. is of great physiological and clinical sig- The analyzer circuit of the apparatus is then flushed with (DLo,) tank oxygen. A sealed bag containing a volume of 0.3 nificance (1). Its measurement, however, is rela- per cent CO and 10 per cent He in air (or in oxygen)2 tively complex (2). Pulmonary diffusing capac- equal to the subject's one second vital capacity is attached ity for carbon monoxide (DLco) which, it is to the three-way tap, the clamps on the bag are removed usually assumed,' can be converted to DL02 from and the bag and analyzer circuit mixed by the pump.3 the known solubilities and molecular weights of A bag-in-box device attached to a spirometer has been found convenient for filling the bag.
    [Show full text]
  • Making the Diagnosis of Asthma
    Making the Diagnosis of Asthma Meredith C McCormack MD MHS and Paul L Enright MD Introduction Signs and Symptoms Differential Diagnosis Diagnostic Testing Spirometry Bronchodilator Response Testing Inhalation Challenge Test Radioallergosorbent Test and Allergen Skin Test Exhaled Nitric Oxide Radiographic Imaging Asthma Versus Chronic Obstructive Pulmonary Disease Asthma Severity Summary: Take-Home Messages for the Respiratory Therapist Diagnostic tests can only increase or decrease the probability of the asthma diagnosis, so a thorough history is very important. In patients with asthma-like symptoms, spirometric evidence of airway obstruction plus a large bronchodilator response makes asthma much more likely. However, nor- mal spirometry is common in patients with mild asthma who are not symptomatic at the time of testing, and patients with poorly controlled asthma may lack substantial bronchodilator response. Inhalation challenge test often helps confirm asthma in patients with normal spirometry. Adult smokers with intermittent respiratory symptoms may have either asthma or chronic obstructive pulmonary disease (COPD). Normal post-bronchodilator spirometry rules out COPD. In patients with airway obstruction, a low diffusing capacity of the lung for carbon monoxide increases the probability of COPD and makes asthma much less likely. A high exhaled nitric oxide level makes allergic asthma more likely. Response to inhaled corticosteroids makes asthma more likely and COPD less likely. Key words: asthma, spirometry, methacholine, bronchodilator, pulmonary function, diagnosis. [Respir Care 2008;53(5):583–590. © 2008 Daedalus Enterprises] Meredith C McCormack MD MHS is affiliated with the Division of consulting on spirometry quality-assurance programs for a phase-3 clin- Pulmonary and Critical Care Medicine, Johns Hopkins School of Med- ical trial of varenicline for smoking cessation.
    [Show full text]
  • Performance Characteristics in Idiopathic Pulmonary Fibrosis
    ORIGINAL ARTICLE INTERSTITIAL LUNG DISEASE AND RADIOLOGY Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis Stephen M. Humphries1, Jeffrey J. Swigris2, Kevin K. Brown2, Matthew Strand3, Qi Gong4, John S. Sundy4, Ganesh Raghu5, Marvin I. Schwarz6, Kevin R. Flaherty7, Rohit Sood8, Thomas G. O’Riordan4 and David A. Lynch1 Affiliations: 1Dept of Radiology, National Jewish Health, Denver, CO, USA. 2Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, USA. 3Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, CO, USA. 4Gilead Sciences Inc., Foster City, CA, USA. 5Center for Interstitial Lung Diseases, Dept of Medicine, University of Washington, Seattle, WA, USA. 6Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado, Aurora, CO, USA. 7Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA. 8PAREXEL International, Billerica, MA, USA. Correspondence: Stephen M. Humphries, Quantitative Imaging Laboratory, Dept of Radiology, National Jewish Health, 1400 Jackson Street, Denver, CO 80206-2761, USA. E-mail: [email protected] @ERSpublications In subjects with IPF, quantification of lung fibrosis extent on HRCT using data-driven texture analysis shows acceptable performance characteristics and minimal clinically important difference in the range of 3.4–6.4% http://ow.ly/fFNc30lfAGh Cite this article as: Humphries SM, Swigris JJ, Brown KK, et al. Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis. Eur Respir J 2018; 52: 1801384 [https://doi.org/10.1183/13993003.01384-2018]. ABSTRACT We evaluated performance characteristics and estimated the minimal clinically important difference (MCID) of data-driven texture analysis (DTA), a high-resolution computed tomography (HRCT)-derived measurement of lung fibrosis, in subjects with idiopathic pulmonary fibrosis (IPF).
    [Show full text]
  • Methacholine Challenge Test 1 2
    Methacholine Challenge Test 1 2 What is Methacholine Challenge Test (MCT)? Also, • Do not consume a heavy meal within 2 hours of the test. You can have a light It is a test that measures if your airways narrow after inhaling specific provoking meal e.g. sandwich, soup or salad within 2 hours before the test. agent. The provoking agent used in this test is inhaled methacholine. The degree • Do not wear any tight clothes. of resultant airway narrowing is dependent on each individual’s susceptibility and this airway narrowing will be assessed objectively by measuring the lung function You may also need to stop certain medications before taking the test depending on what clinical questions your physician would like answered based on your MCT changes before and after inhalation of the methacholine in progressively larger results. Different medications have to be stopped at different times before the test doses. Increased airway hyperresponsiveness is usually a hallmark feature of asthma. depending on how long they stay in your body. It is important for you to check with your doctor regarding the safety of stopping Why do I need this operation/procedure? these medications before discontinuing them for the test. Commonly, if you had presented with respiratory symptoms such as shortness of How long before the test? Avoid the following: breath, wheezing, chest tightness or cough, 6weeks Omalizumab your physician may consider doing a MCT to 1week Tiotropium (Spiriva) establish the diagnosis of asthma, especially if 48hours Combination inhalers such as Seretide (fluticasone/ initial lung function tests have not confirmed salmeterol) or Symbicort (budesonide/formoterol) or the diagnosis.
    [Show full text]
  • Standardisation of Spirometry
    Eur Respir J 2005; 26: 319–338 DOI: 10.1183/09031936.05.00034805 CopyrightßERS Journals Ltd 2005 SERIES ‘‘ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING’’ Edited by V. Brusasco, R. Crapo and G. Viegi Number 2 in this Series Standardisation of spirometry M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, R. Crapo, P. Enright, C.P.M. van der Grinten, P. Gustafsson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. Pellegrino, G. Viegi and J. Wanger CONTENTS AFFILIATIONS Background ............................................................... 320 For affiliations, please see Acknowledgements section FEV1 and FVC manoeuvre .................................................... 321 Definitions . 321 CORRESPONDENCE Equipment . 321 V. Brusasco Requirements . 321 Internal Medicine University of Genoa Display . 321 V.le Benedetto XV, 6 Validation . 322 I-16132 Genova Quality control . 322 Italy Quality control for volume-measuring devices . 322 Fax: 39 103537690 E-mail: [email protected] Quality control for flow-measuring devices . 323 Test procedure . 323 Received: Within-manoeuvre evaluation . 324 March 23 2005 Start of test criteria. 324 Accepted after revision: April 05 2005 End of test criteria . 324 Additional criteria . 324 Summary of acceptable blow criteria . 325 Between-manoeuvre evaluation . 325 Manoeuvre repeatability . 325 Maximum number of manoeuvres . 326 Test result selection . 326 Other derived indices . 326 FEVt .................................................................. 326 Standardisation of FEV1 for expired volume, FEV1/FVC and FEV1/VC.................... 326 FEF25–75% .............................................................. 326 PEF.................................................................. 326 Maximal expiratory flow–volume loops . 326 Definitions. 326 Equipment . 327 Test procedure . 327 Within- and between-manoeuvre evaluation . 327 Flow–volume loop examples. 327 Reversibility testing . 327 Method .
    [Show full text]
  • Expiratory Capnography in Asthma
    Eur Respir J, 1994, 7, 318–323 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07020318 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Expiratory capnography in asthma: B. You*, R. Peslin**, C. Duvivier**, V. Dang Vu*, J.P. Grilliat* Expiratory capnography in asthma: evaluation of various shape indices. B. You, R. *U.M.G., Service de Médecine H, Hôpital Peslin, C. Duvivier, V. Dang Vu, J.P. Grilliat. ERS Journals Ltd 1994. Central, Nancy, France. **INSERM, Unité ABSTRACT: The shape of the capnogram is modified by airway obstruction, and 14, Physiopathologie Respiratoire, Vandœuvre- the evaluation of this deformation, using measurable indices, could allow an indi- les- Nancy, France. rect measurement of bronchial patency. A previous study undertaken in asthmat- Correspondence: B. You ic subjects showed a good correlation between a capnographic index (end-tidal slope) 19 Avenue du Vieux Château and a spirometric parameter (forced expiratory volume in one second as a per- Vandœuvre-les-Nancy centage of predicted (FEV1 %pred)) and suggested the study of other indices. 54500 The correlations between capnographic and spirometric indices were measured France in 10 healthy subjects and 30 asthmatic patients. The usefulness of eight descriptive indices, analysing the successive phases of the capnogram, was assessed by measur- Keywords: Asthma ing their reproducibility and their sensitivity to airway obstruction. The intra- capnography individual and interindividual variabilities (Vi and VI) and the noise/signal ratio carbon dioxide lung function tests (Vi/VI) were measured by comparing the results of two successive capnographic monitoring measurements in 14 asthmatic subjects.
    [Show full text]
  • Study of Pleurodesis Using Ethanolamine Oleate Through Ultrasound-Guided Pigtail Adel M
    Original article 253 Study of pleurodesis using ethanolamine oleate through ultrasound-guided pigtail Adel M. Saeeda, Tamer M. Alia, Ashraf A. Gomaaa, Mohamed N. Kamelb Background Malignant pleural effusion (MPE) is a common treatment, the management of MPE remains palliative, with and serious condition that is associated with poor quality of median survival ranging from 3 to 12 months. life, morbidity and mortality. Results Complete response was 81.8% of studied cases, Aim Study of pleurodesis using ethanolamine oleate (ETH) while no/partial response was 18.2%. Pleurodesis through ultrasound-guided pigtail to evaluate the efficacy and complications were fever (21.1%), chest pain (33.3%), complications of ETH and pigtail. nausea (24.2%), vomiting (12.1%) and hypotension (6.1%). Pigtail complications were pigtail obstruction (3.03%), chest Design Thirty-three patients with MPE were included and pain (3.03%) and obstruction and pain (12.12%) of the were subjected to history taking, clinical examination, chest studied cases. There was a decrease in FVC% and FEV1% 2 radiographs (on admission, every day before pleurodesis to months after pleurodesis. However, no significant difference ensure complete lung expansion and to exclude as regards actual (measured) FEV1/FVC% before and 2 pneumothorax, every day after pleurodesis till the removal of months after pleurodesis in all cases. Whereas, complete the catheter and on follow-up − 2 months after pleurodesis − response was 81.8% by CXR and chest ultrasound. to check for reaccumulation of pleural effusion), chest sonography, pleural tapping, chest computed tomography Conclusion ETH injection through pigtail was safe and scan (in some patients), pleural biopsy using Abram’s needle effective in pleurodesis of MPE.
    [Show full text]
  • ERS Technical Standard on Bronchial Challenge Testing: Pathophysiology and Methodology of Indirect Airway Challenge Testing
    ERJ Express. Published on October 25, 2018 as doi: 10.1183/13993003.01033-2018 Early View Task force report ERS Technical Standard on Bronchial Challenge Testing: Pathophysiology and Methodology of Indirect Airway Challenge Testing Teal S. Hallstrand, Joerg D. Leuppi, Guy Joos, Graham L. Hall, Kai-Håkon Carlsen, David A. Kaminsky, Allan L. Coates, Donald W. Cockcroft, Bruce H. Culver, Zuzana Diamant, Gail M. Gauvreau, Ildiko Horvath, F. H. C. de Jongh, Beth L. Laube, P. J. Sterk, Jack Wanger Please cite this article as: Hallstrand TS, Leuppi JD, Joos G, et al. ERS Technical Standard on Bronchial Challenge Testing: Pathophysiology and Methodology of Indirect Airway Challenge Testing. Eur Respir J 2018; in press (https://doi.org/10.1183/13993003.01033-2018). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©ERS 2018 Copyright 2018 by the European Respiratory Society. ERS Technical Standard on Bronchial Challenge Testing: Pathophysiology and Methodology of Indirect Airway Challenge Testing. Teal S. Hallstrand1, Joerg D. Leuppi2, Guy Joos3, Graham L. Hall4, Kai-Håkon Carlsen5, David A. Kaminsky6, Allan L. Coates7, Donald W. Cockcroft8, Bruce H. Culver1, Zuzana Diamant9,10, Gail M. Gauvreau11, Ildiko Horvath12, F.H.C. de Jongh13,
    [Show full text]